BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29554108)

  • 1. The economic burden of rotavirus infection in South Korea from 2009 to 2012.
    Lee KS; Lee YR; Park SY; Oh IH
    PLoS One; 2018; 13(3):e0194120. PubMed ID: 29554108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic Impact of the Rotavirus Vaccine in Korea: Comparing the Epidemiologic and Economic Characteristics of Rotavirus Gastroenteritis Before and After the Introduction of Vaccines.
    Cho H; Lee H; Kim DS; Kim HM; Kim JH; Kim AY; Kang HY
    Pediatr Infect Dis J; 2020 May; 39(5):460-465. PubMed ID: 31990891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
    Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
    J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the national immunization program of rotavirus vaccination for children in Korea.
    Kang HY; Kim KH; Kim JH; Kim HM; Kim J; Kim MS; El Khoury AC; Kim DS
    Asia Pac J Public Health; 2013 Mar; 25(2):145-58. PubMed ID: 22234827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
    Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
    Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt.
    Ortega O; El-Sayed N; Sanders JW; Abd-Rabou Z; Antil L; Bresee J; Mansour A; Adib I; Nahkla I; Riddle MS
    J Infect Dis; 2009 Nov; 200 Suppl 1():S92-8. PubMed ID: 19817621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
    J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Tucker AW; Haddix AC; Bresee JS; Holman RC; Parashar UD; Glass RI
    JAMA; 1998 May; 279(17):1371-6. PubMed ID: 9582045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom.
    Lorgelly PK; Joshi D; Iturriza Gómara M; Gray J; Mugford M
    Epidemiol Infect; 2008 Jan; 136(1):44-55. PubMed ID: 17335631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
    Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
    PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean.
    Takemoto ML; Bahia L; Toscano CM; Araujo DV
    Vaccine; 2013 Jul; 31 Suppl 3():C45-57. PubMed ID: 23777691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.